Also known as gw 610742, fitorine · Wikipedia
GW-0742 (sometimes labelled GW-610742) is a small-molecule selective PPAR-delta (PPARbeta/delta) agonist developed as a research tool compound - it is NOT a peptide. Preclinical studies have characterised it as an exercise-mimetic that upregulates fatty-acid oxidation, mitochondrial biogenesis, and oxidative muscle-fiber gene programs, and exerts anti-inflammatory effects via NF-kB suppression (Cheng et al., 2004; Sahebkar et al., 2014). Its structural sister molecule, GW-501516 (cardarine), caused multiple tumour types in long-term rodent carcinogenicity studies, and GSK halted that program. GW-0742 has no human clinical trial development and is sold only as a research chemical. WADA prohibits PPAR-delta agonists at all times (S4.5).
—
best
price
—
per
mg
—
vendors
tracked
Preclinical
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
GW-0742 is a small-molecule selective agonist of the peroxisome proliferator-activated receptor delta (PPAR-delta / PPAR-beta), with high selectivity over PPAR-alpha and PPAR-gamma. Activated PPAR-delta heterodimerises with RXR and binds peroxisome proliferator response elements (PPREs) on target genes.
Pharmacokinetic properties
Half-life
Approximately 8-24 hours in preclinical models; human PK not characterized
Routes
oral
Bioavailability
Designed as an orally bioavailable small molecule; standard formulations are oral tablets/suspension. No injectable use rationale.
Amino-acid sequence
[4-[[[2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenyloxy]acetic acid
Use & research dosing
There is no human clinical dose for GW-0742. Preclinical rodent studies have generally used 1-10 mg/kg/day orally for short courses. Self-experimentation protocols, where they exist, are typically modelled on cardarine (GW-501516) at 5-15 mg/day orally for cycles of 4-8 weeks. These protocols are not supported by any controlled human PK, safety, or efficacy data, and the rodent carcinogenicity signal seen with the sister molecule GW-501516 should be assumed to apply to this class until proven otherwise. No formal dose-finding has been performed.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Knowledge-base content for GW-0742 must clearly flag two things: (1) it is not a peptide - it is a small-molecule PPAR-delta agonist - and (2) the structurally related cardarine (GW-501516) caused multiple tumour types in long-term rodent carcinogenicity studies, leading GSK to halt development; WADA has issued an explicit health-risk alert about cardarine. GW-0742 cannot be assumed safe by analogy. There is no IND-stage clinical program. All sales are research-only.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.